Welcome to the Kuros Biosciences Full Year 2025 Financial Report. I will now hand over to Alex Muller from Investor Relations. Please go ahead. Thank you, operator, and good afternoon or good morning, ...
Earnings call Kuros Biosciences posted FY25 revenue of $146.1M (+72% YoY), adjusted EBITDA of $19.6M (13.4% margin), and first-ever net profit of $2.6M, exceeding guidance. Management guides for at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results